How to appeal a Humana pediatric epilepsy denial
42 CFR Part 422 Subpart M (Medicare Advantage) · 60-day window · 30-day decision
To appeal a Humana pediatric epilepsy denial, file an internal appeal within 60 days of the date on the denial letter through Humana's member or provider portal, under 42 CFR Part 422 Subpart M (Medicare Advantage). Humana returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).
Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
What Humana's policy requires for pediatric epilepsy
Cited policy: Humana Ztalmy (Ganaxolone) for CDKL5 Deficiency Disorder
Confirmed CDKL5 pathogenic / likely-pathogenic variant on genetic testing (panel / WES / WGS report attached). Age >=2 yr per Mar 18, 2022 label. Pediatric epileptologist / neurologist Rx. Failed >=1 prior AED (typical CDD patients have failed 4-7). Reauth at 6 mo with documented seizure reduction.
How Humana denies pediatric epilepsy — and how to counter it
Where Humana pushes back: 1) Genetic confirmation insufficient; 2) Try other AEDs first; 3) Off-label for non-CDKL5 epilepsy; 4) Variant of uncertain significance not eligible.
Counter-arguments that hold up: FDA-approved Mar 18, 2022 specifically for CDKL5 deficiency disorder >=2 yr — first-ever drug for CDD. Marigold Knight Lancet Neurol 2022 — 30.7% reduction in major motor seizures vs 6.9% placebo. Submit CDKL5 variant report (gene + variant + lab + ACMG classification — pathogenic or likely-pathogenic). CDD patients are inherently drug-resistant — average 4-7 prior AED failures (Olson Pediatr Neurol 2019). Not seeking off-label use; exact FDA indication. AAN/AES 2018 Hill genetic-testing guideline supports CDKL5 panel as part of standard pediatric epilepsy workup.
What Humana typically denies for pediatric epilepsy
Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric epilepsy, expect:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Treatments most often denied in this category
These are the pediatric epilepsy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Epidiolex
- Fintepla
- Diacomit
- Clobazam (Onfi/Sympazan)
- Banzel
- Ztalmy (CDKL5)
How to submit the appeal to Humana
- Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
- File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Humana pediatric epilepsy denial?
Humana allows 60 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Humana appeal?
Members can submit through the Humana member portal at https://www.humana.com. Providers should use the provider portal at https://www.humana.com/provider. Faxed and mailed appeals are accepted but take longer.
What denials does Humana most often issue for pediatric epilepsy?
For pediatric epilepsy, Humana most often denies on: 1) Genetic confirmation insufficient; 2) Try other AEDs first; 3) Off-label for non-CDKL5 epilepsy; 4) Variant of uncertain significance not eligible. The strongest counters: FDA-approved Mar 18, 2022 specifically for CDKL5 deficiency disorder >=2 yr — first-ever drug for CDD. Marigold Knight Lancet Neurol 2022 — 30.7% reduction in major motor seizures vs 6.9% placebo. Submit CDKL5 variant report (gene + variant + lab + ACMG classification — pathogenic or likely-pathogenic). CDD patients are inherently drug-resistant — average 4-7 prior AED failures (Olson Pediatr Neurol 2019). Not seeking off-label use; exact FDA indication. AAN/AES 2018 Hill genetic-testing guideline supports CDKL5 panel as part of standard pediatric epilepsy workup.
What if Humana denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Pediatric epilepsy appeal
Upload your Humana denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to 42 CFR Part 422 Subpart M (Medicare Advantage).
Get started →Contact: hello@denialhelp.com